Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and β-oxidation in skeletal muscle

M Furuhashi, N Ura, H Murakami, M Hyakukoku, K Yamaguchi, K Higashiura and K Shimamoto
Second Department of Internal Medicine, Sapporo Medical University School of Medicine, S-1, W-16, Chuo-ku, Sapporo 060–8543, Japan

(Requests for offprints should be addressed to M Furuhashi; Email: furuhashi@sapmed.ac.jp)

Abstract

We investigated the effect of fenofibrate, a peroxisome proliferator-activated receptor-α agonist, on insulin sensitivity including lipid metabolism in skeletal muscle. Six-week-old male Sprague–Dawley rats were divided into two groups: those fed a standard chow (control) or a fructose-rich chow (fructose-fed rats (FFRs)) for 6 weeks. FFRs were treated either with a vehicle or with 30 mg/kg per day of fenofibrate for the last 2 weeks. Insulin sensitivity (M-value) was estimated by the euglycemic hyperinsulinemic glucose clamp method. Fatty acid-binding protein (FABP) in skeletal muscle was measured by ELISA, and the expression of FABP mRNA was analyzed by semi-quantitative RT-PCR. The serum and muscle triglyceride (sTG and mTG) levels and the activity of 3-hydroxyacyl-CoA dehydrogenase (HADH), a β-oxidation enzyme, in muscle were also determined. FFRs showed a lower M-value and higher blood pressure, sTG and mTG than did the control group. The mTG was correlated positively with sTG and negatively with the M-value. Fenofibrate treatment for 2 weeks did not change blood pressure but significantly improved the M-value, sTG and mTG. FABP content and mRNA in the soleus muscle were significantly elevated in FFRs compared with those in the control group. Fenofibrate treatment further increased FABP. The HADH activity was comparable between the control group and FFRs, but significantly increased by fenofibrate treatment. These results suggest that fenofibrate improves insulin sensitivity not only by lowering serum lipids and subsequent influx of fatty acids into muscles but also by reducing intramuscular lipid content via further induction of FABP and stimulation of β-oxidation in muscles.


Introduction

Insulin resistance and accompanying hyperinsulinemia have been reported to play an important role in the onset and progression of hypertension, dyslipidemia and atherosclerosis (Reaven 1988, Kaplan 1989, DeFronzo & Ferrannini 1991, Limura 1996). It has also been reported that accumulation of lipid content in skeletal muscle can interfere with insulin action and result in insulin resistance (Storlien et al. 1991, Goodpaster et al. 1997, Pan et al. 1997, Kelley & Mandarino 2000).

Fatty acid-binding proteins (FABPs) are low-molecular-weight cytosolic proteins (14–15 kDa) found in various cell types. The FABP found in skeletal muscle was shown to be identical with heart-type FABP (Peeters et al. 1991). FABPs are thought to play a role in solubilization of long-chain fatty acids and consequently in facilitation of the cytosolic transport of long-chain fatty acids to various intracellular organelles, including the mitochondria, peroxisomes, nucleus and lipid droplets (Storch & Thumser 2000). It has been suggested that FABPs are concerned with mitochondrial and peroxisomal β-oxidation, gene transcription and cell growth/differentiation, and incorporation of fatty acids into triglyceride (Veerkamp & van Moerkerk 1993, Glatz et al. 1995, Borchers et al. 1997, Zanotti 1999).

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor superfamily, which are involved in gene regulation and are important regulators of glucose and lipid homeostasis (Schoonjans et al. 1997). Whereas thiazolidinediones are insulin sensitizers acting via activation of PPARγ, fibrates exert lipid-lowering activity via PPARα. Fibrate treatment regulates lipoprotein metabolism (Staels et al. 1998), fatty acid oxidation (Meertens et al. 1998) and the cellular transport of fatty acids (Motojima et al. 1998) in the liver. Since the PPARα protein is also expressed in skeletal muscle as well as in the liver (Su et al. 1998), fibrates also seem to be associated with intracellular lipid metabolism in skeletal muscles. It is noteworthy that the promoter of muscle
FABP has peroxisome proliferator responsive elements (Treuner et al. 1994).

Some studies have shown that fibrates also improved glucose tolerance or increased insulin sensitivity in humans (Jones et al. 1990, Inoue et al. 1994, Yong et al. 1999, Idzior-Walus et al. 2000) and rodents (Matsui et al. 1997, Guerre-Millo et al. 2000, Ye et al. 2001). However, in most of these studies, a gold standard assessment such as the euglycemic hyperinsulinemic glucose clamp method was not used. The mechanisms of these effects are also unclear. We therefore investigated the effect of fenofibrate, a highly selective PPARα activator, on glucose homeostasis and its relationship to intramuscular lipid content, muscle FABP and muscle β-oxidation in fructose-fed rats (FFRs) as an animal model of insulin resistance and hypertension.

**Materials and Methods**

**Protocol 1**

As a preliminary study, 12-week-old male Sprague–Dawley rats (n = 15) obtained from Charles River Japan Inc. (Yokohama, Japan) were used. The care of the animals was in strict accordance with the guiding principles of the Physiological Society of Japan. All rats were fed a standard rat chow containing 60% vegetable starch, 5% fat and 24% protein (Oriental Yeast Co., Tokyo, Japan). They were maintained on a 12 h light:12 h cycle and with freely available water and chow. Insulin sensitivity was estimated by the euglycemic hyperinsulinemic glucose clamp method, and soleus muscle was prepared under sodium pentobarbital anesthesia. The lipid content in the soleus muscle was extracted and measured.

**Protocol 2**

**Animals** Male Sprague–Dawley rats of 6 weeks of age were used for all experiments. Prior to any manipulation, all rats were fed standard rat chow. The rats were divided into two groups at the start of the study: those fed a standard rat chow (control group, n = 10) or those given a fructose-rich chow containing 60% fructose, 5% fat, and 20% protein (#78463; Teklad, WI, USA) for 6 weeks. FFRs were treated by oral gavage either with a vehicle 20% protein (#78463; Teklad, WI, USA) for 6 weeks. FFRs were treated by oral gavage either with a vehicle 20% protein (#78463; Teklad, WI, USA) for 6 weeks.

**Blood pressure and pulse rate measurements** Systolic blood pressure and pulse rate were measured in all conscious rats using an indirect tail-cuff method (BP-98A; Softran, Tokyo, Japan) on a 37 °C preheated cloth jacket for 10 min. An average of five recordings was taken as each individual value.

**Determination of serum variables** Blood samples were collected from the tail vein after 12 h deprivation of food. Serum was prepared by centrifugation at 2000 g for 15 min at 4 °C and stored at −20 °C until use for measurement of serum insulin and lipids. Rat serum insulin was measured with an enzyme immunoassay kit (Morinaga Seikagaku, Yokohama, Japan). Serum levels of triglyceride and free fatty acid were determined by enzymatic colorimetric methods using commercially available test kits (Wako Chemicals, Osaka, Japan) and a U-1100 spectrophotometer (Hitachi Seisakusyo, Tokyo, Japan).

**Euglycemic hyperinsulinemic glucose clamp technique** At the end of the treatment period, rats were anesthetized i.p. with sodium pentobarbital (50 mg/kg). The right common carotid artery and the right jugular vein were exposed and cannulated with a polyethylene tube (PE50; Becton Dickinson and Co., Sparks, MD, USA) for collection of blood samples and administration of the infusate respectively. Each rat was placed in a foam plastic jacket that allowed movement of all four limbs and forward vision after overnight fasting (approximately 12 h). At the start of the glucose clamp, fasting blood glucose was measured by the glucose oxidase method using an ExacTech 2A glucose analyzer (MediSense, Waltham, MA, USA). The initial load of insulin (25 mU/kg of Humulin R, U-40; Shionogi Pharmaceutical Co., Osaka, Japan) was infused by a bolus, and this was followed by a constant infusion of insulin at a rate of 4 mU/kg per min for 154 min. During the glucose clamp, 12·5% glucose solution was infused as needed to maintain blood glucose at the fasting level. Ten microliters of arterial blood were sampled at 7 min intervals for determination of blood glucose. The average of the rate of glucose infusion for the last 35 min was taken as an index of insulin sensitivity (M-value; mg/kg per min) (Higashiura et al. 1997).

**Tissue preparation** Rats were anesthetized i.p. with sodium pentobarbital (50 mg/kg) and perfused with 150 ml sterile saline through the apex of the left ventricle. Soleus (containing mainly slow-twitch oxidative fibers, type I) and extensor digitorum longus (EDL, containing a mixture of fast-twitch oxidative-glycolytic, type IIa and glycolytic fibers, type IIb) muscles (Ariano et al. 1973) were employed as red and white muscle respectively, and were dissected and immediately frozen in liquid nitrogen. Muscle samples were stored at −70 °C until use.

**Skeletal muscle triglyceride** Total lipid extracts of skeletal muscles were obtained by the method previously described.
described (Folch et al. 1957) using 2:1 (v/v) chloroform–methanol. These extracts were then dried under a nitrogen stream, dissolved in 2·0 ml 100:1 (v/v) chloroform–acetic acid, and applied to a Sep-Pak Silica cartridge (Waters, Milford, MA, USA) for separation of phospholipids. The fraction including triglyceride was eluted with 14 ml additional 100:1 chloroform–acetic acid (Hamilton & Comai 1984). A known volume of the fraction was evaporated to dryness using nitrogen. Triglyceride content was determined spectrophotometrically using a test kit as stated above.

Muscle FABP content All steps were performed on ice. Muscles were cut and homogenized (2·5%, w/v) in ice-cold PBS (pH 7·4) using a Polytron (Kinematica, Lucerne, Switzerland). Tissue homogenates were centrifuged at 15 000 g for 15 min at 4 °C to remove cell debris. The tissue content of cytosolic FABP was measured with a sandwich ELISA kit (HyCult Biotechnology, Uden, Netherlands) using murine monoclonal IgG antibodies directed against purified FABP. Total protein concentration was determined with a bicinchoninic acid kit (Protein Assay No. 23225; Pierce, Rockford, IL, USA) using BSA as a standard (Smith et al. 1985).

RNA extraction and analysis In all steps of the procedure, 0·1% diethyl pyrocarbonate (DEPC)-treated water was used. Total RNA was isolated according to the modified method as previously described (Chomczynski & Sacchi 1987) using Trizol reagent (Life Technologies, MD, USA) and dissolved in DEPC-treated water for direct use or stored in 70% ethanol at −70 °C. Semiquantitative RT-PCR was performed to assess mRNA expression. The PCR primers used were an oligo (dT) first-strand primer and two pairs of specific primers based on previously reported sequences: 5′-TTGCACCATGG CGGACGCCCTTT-3′ and 5′-AGTGACGGGGGAGC CAGTGTCACGCCTCTTT-3′ for muscle FABP (Van Nieuwenhoven et al. 1994), and 5′-CTGATCCACA TCTGCTGGAAGGTGG-3′ and 5′-ACCTTCAACAC CCCAGCCATGTACG-3′ for β-actin (Wu et al. 2000) as a housekeeping gene and internal control. The PCR product from an RNA template was obtained with Ready-To-Go RT-PCR Beads (Amersham Pharmacia Biotech, Tokyo, Japan) containing Moloney murine leukemia virus reverse transcriptase and Taq DNA polymerase. The reaction mixture contained 2 µg total RNA, the first-strand primer, one pair of specific primers, and DEPC-treated water in a total volume of 50 µl. A one-step protocol for RT-PCR was performed using a PCR Thermal Cycler SP (TP400; Takara Shuzo Co., Shiga, Japan) according to the following scheme: (i) 15 min first-strand synthesis at 42 °C; (ii) 5 min inactivation of reverse transcriptase and denaturation at 95 °C; (iii) optimized cycles depending on the target (FABP of the soleus, 16 cycles; FABP of the EDL, 22 cycles; β-actin of both muscles, 22 cycles) of 30 s at 95 °C (denaturation), 30 s at 59 °C (annealing), 30 s at 72 °C (elongation); and (iv) finally 7 min at 72 °C (final extension). Preliminary experiments confirmed that each PCR product was performed within the linear phase of the PCR amplified reaction. Each sample was electrophoresed on 1·5% agarose gel and stained with ethidium bromide. The intensity of the ethidium bromide luminescence was detected by charge coupled device (CCD) imaging (COMPACT BIS; Amersham Pharmacia Biotech) and analyzed using SigmaGel software (SPSS Inc., Chicago, IL, USA).

Enzymatic activities Activities of 3-hydroxyacyl-CoA dehydrogenase (HADH, EC 4.1.3.7) and citrate synthase (EC 4.1.3.7) were measured spectrophotometrically at 37 °C in supernatants of muscle homogenates (Osumi & Hashimoto 1979, Sreer 1969). Enzyme activities are expressed in µmol/min per g wet weight of tissue.

Statistical analysis All numeric variables are expressed as means ± S.E.M. Group statistical comparisons were assessed by one-way ANOVA and individual comparisons by Fisher post hoc tests. Regression analyses were used to compare relationships. A P value of <0·05 was considered statistically significant.

Results

Protocol 1

Intramuscular triglyceride content in the soleus muscle of Sprague–Dawley rats (n=15) was negatively correlated with the M-value as an index of insulin sensitivity (r= −0·67, P<0·05; Fig. 1).

Protocol 2

Physical and biochemical findings (Table 1) There were no inter-group differences in body weight, pulse rate and fasting blood glucose. Systolic blood pressure was significantly higher in FFRs than in control rats. The average rate of glucose infusion during the last 35 min of the glucose clamp, as an index of insulin sensitivity (M-value), was significantly lower in FFRs than in control rats. Fenofibrate treatment for 2 weeks did not change blood pressure in FFRs but significantly improved the M-value in FFRs. A high fructose diet significantly increased serum insulin, triglyceride and free fatty acid levels. Fenofibrate treatment essentially reversed the serum insulin and lipids concentrations. In particular, the serum triglyceride was significantly lower in the FFR+FF group than in the FFR and control groups.

Muscle triglyceride content FFRs showed a significant increase in the triglyceride content of the soleus muscle.
compared with that in the control group (Fig. 2A). Both serum triglyceride and free fatty acid levels were significantly correlated with the triglyceride content in the soleus muscle (Fig. 3). The lipid content of the EDL muscle in FFRs maintained its tendency to be higher than that in the control group (5·8±1·0 and 8·6±1·1 µmol/g wet weight of tissue for the control and FFR groups respectively, P<0·06; Fig. 2B). Fenofibrate treatment recovered the intramuscular triglyceride to the same level as that of the control group.

**FABP in muscle tissue** Cytosolic FABP content of the soleus muscle was significantly elevated in FFRs compared with that in the control rats (2·3±0·1 and 3·1±0·2 mg/g protein for the control and FFR groups respectively, P<0·05). Fenofibrate treatment further increased the FABP content of the soleus muscle (5·3±0·5 mg/g protein, P<0·01 vs other groups; Fig. 4A). The FABP content of the soleus muscle was approximately 4-fold higher than that of the EDL muscle in the control group.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Control (n=10)</th>
<th>FFR (n=10)</th>
<th>FFR+FF (n=7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (g)</td>
<td>384±5</td>
<td>388±4</td>
<td>388±10</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>127±2</td>
<td>137±2*</td>
<td>136±2*</td>
</tr>
<tr>
<td>Pulse rate (beats/min)</td>
<td>329±7</td>
<td>329±8</td>
<td>317±6</td>
</tr>
<tr>
<td>M-value (mg/kg per min)</td>
<td>16·3±0·8</td>
<td>12·4±1·1*</td>
<td>15·9±0·9*</td>
</tr>
<tr>
<td>Fasting blood glucose (mmol/l)</td>
<td>4·7±0·2</td>
<td>5·0±0·2</td>
<td>5·1±0·1</td>
</tr>
<tr>
<td>Fasting insulin (pmol/l)</td>
<td>128±24</td>
<td>343±31*</td>
<td>107±23*</td>
</tr>
<tr>
<td>Triglyceride (mmol/l)</td>
<td>1·34±0·11</td>
<td>2·55±0·27*</td>
<td>0·68±0·05†‡</td>
</tr>
<tr>
<td>Free fatty acid (mmol/l)</td>
<td>1·23±0·07</td>
<td>1·53±0·06*</td>
<td>1·03±0·07‡</td>
</tr>
</tbody>
</table>

Table 1 Physical and biochemical characteristics of rats at 12 weeks of age. Values are means±s.e.m.

FFR, fructose-fed rat; FF, fenofibrate.

*P<0·01 vs control; †P<0·05 vs control; ‡P<0·01 vs FFRs; §P<0·05 vs FFRs.
No significant inter-group difference in the FABP content of the EDL muscle was observed (Fig. 4B). The expression of FABP mRNA analyzed by RT-PCR was similar to that of FABP protein in each muscle (Fig. 5).

Enzymatic activities (Table 2) The activities of the β-oxidation enzyme HADH in both muscles were comparable in the control and FFR groups. Fenofibrate increased HADH activity significantly in the soleus muscle (11.5 ± 0.5 and 16.6 ± 1.3 µmol/min per g wet weight of tissue in the FFR and FFR+FF groups respectively, \(P<0.01\)), but not in the EDL muscle (4.1 ± 0.4 and 5.4 ± 0.6 µmol/min per g wet weight of tissue in the FFR and FFR+FF groups respectively, \(P=0.07\)). The activity of the mitochondrial enzyme citrate synthase in muscles was not significantly different among the three groups. The soleus muscle exhibited greater HADH and citrate synthase activities than did the EDL.

Discussion

There are few reports on the effects of fibrates (PPARα agonists) on insulin sensitivity. Some studies have demonstrated that bezafibrate normalized impaired glucose tolerance in both human and rodent models of insulin resistance (Jones et al. 1990, Inoue et al. 1994, Matsui et al. 1997). However, bezafibrate activates PPARα, PPARγ and PPARδ with almost comparable EC_{50} values (PPARα: 50; PPARγ: 60; PPARδ: 20 µM in humans, PPARα: 90; PPARγ: 55; PPARδ: 110 µM in rodents, for reference see Brown et al. (1999)). Therefore, it is impossible to conclude that PPARα activation improves glucose metabolism, since PPARγ agonists are known to be insulin sensitizers. In the present study, fenofibrate was used as a PPARα-selective fibrate (PPARα: 18; PPARγ: 250; PPARδ: >300 µM, for reference see Brown et al. (1999)). Although small-scale studies using human subjects have shown that fenofibrate increased insulin sensitivity as assessed by oral glucose tolerance tests and the serum insulin level (Yong et al. 1999, Idzior-Walus et al. 2000), the mechanisms remain unclarified. Recently, it has been reported that selective

Figure 3 Positive correlation between triglyceride content of the soleus muscle and serum triglyceride (A) or free fatty acid (B) in both the control group (\(n=10\)) and FFR group (\(n=10\)).

Figure 4 Muscle fatty acid-binding protein (FABP) levels in the soleus (A) and EDL (B) muscles in the control group (\(n=10\)), FFR group (\(n=10\)) and FFR+FF group (\(n=7\)). FABP was measured by ELISA. (A) Muscle FABP was elevated by high fructose diet and further induced by FF treatment in the soleus muscle. (B) No significant difference in muscle FABP was observed among the three groups in the EDL muscle. Values are means ± S.E.M. *\(P<0.01\) vs control; †\(P<0.01\) vs control and FFRs.
PPARα agonists such as fenofibrate and Wy14,643 inhibited high fat diet-induced insulin resistance concomitantly with prevention of high fat diet-induced increase in body weight and adipose tissue mass in rodents (Guerre-Millo et al. 2000, Ye et al. 2001). It is unclear, however, whether the effect of PPARα agonists on insulin sensitiv-

ity is a direct action or a secondary action due to a decrease in body weight and adiposity. We therefore used FFRs as a non-obese insulin-resistant hypertension model (Hwang et al. 1987, Reaven et al. 1988) and correctly assessed insulin sensitivity by the euglycemic hyperinsulinemic glucose clamp method. The results showed that fenofibrate increased the M-value in FFRs, indicating an improvement in insulin sensitivity without influencing body weight as well as fat mass weight (data not shown).

Skeletal muscle plays important roles not only in insulin-mediated glucose metabolism, which accounts for more than 80% of whole body glucose disposal (DeFronzo et al. 1981), but also in the catabolism of fatty acids (Dagenais et al. 1976). Studies in rats and humans have shown that muscle triglyceride content is negatively related to insulin action (Storlien et al. 1991, Goodpaster et al. 1997, Pan et al. 1997, Kelley & Mandarino 2000). This finding was also confirmed in the present study (Fig. 1). A high fructose diet for 6 weeks increased muscle triglyceride content, which was correlated with serum lipids, and might cause insulin resistance together with previously reported mechanisms such as an alteration of muscle fiber composition (Higashiura et al. 1999) and increased tumor necrosis factor-α in skeletal muscle (Togashi et al. 2000). Fenofibrate treatment for 2 weeks might improve insulin sensitivity by lowering muscle triglyceride content in FFRs.

Table 2 Activities of metabolic enzymes in skeletal muscles. Values are means ± S.E.M.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>HADH (µmol/min per g wet tissue)</th>
<th>Citrate synthase (µmol/min per g wet tissue)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Soleus</td>
<td>EDL</td>
</tr>
<tr>
<td>Control (n=10)</td>
<td>11.8 ± 1.0</td>
<td>4.4 ± 0.5</td>
</tr>
<tr>
<td>FFR (n=10)</td>
<td>11.5 ± 0.5</td>
<td>4.1 ± 0.4</td>
</tr>
<tr>
<td>FFR+FF (n=7)</td>
<td>16.6 ± 1.3*</td>
<td>5.4 ± 0.6</td>
</tr>
</tbody>
</table>

HADH, 3-hydroxyacyl-CoA dehydrogenase.

*P<0.01 vs control and FFRs.
concomitant changes in FABP content. A high dietary fat content increased liver-type FABP in the liver and heart-type FABP in the heart (Glatz et al. 1995). It has also been reported that the content of heart-type FABP in the rat heart (Glatz et al. 1994) and red muscle (Carey et al. 1994) was increased in streptozotocin-induced diabetic rats known to increase fatty acid utilization. In the present study, a high fructose diet increased serum triglyceride and free fatty acid levels and also induced muscle FABP content in the soleus muscle. Elevated muscle FABP may facilitate the transport of fatty acids to mitochondria and the catabolism of fatty acids in skeletal muscle (Storch & Thumser 2000). It seems that excess influx of fatty acids into muscles causes accumulation of muscle lipid content because of insufficient elevation of muscle FABP.

PPARα is highly expressed in tissues with elevated rates of fatty acid catabolism, where it regulates genes involved in fatty acid intake, activation into acyl-CoA esters, degradation via the mitochondrial and peroxisomal β-oxidation pathways and ketone body synthesis (Schoonjans et al. 1997). Fibrates induce liver-type FABP (Kaikaus et al. 1993) and β-oxidation enzyme HADH (Zhang et al. 1992) via PPARα activation. PPARα protein is also expressed in skeletal muscle as well as in the liver (Su et al. 1998). The promoter of heart-type FABP (equal to muscle FABP) has peroxisome proliferator responsive elements (Treuner et al. 1994) as well as that of liver-type FABP (Iseemann et al. 1992) and HADH (Zhang et al. 1992). It has also been reported that heart-type FABP is expressed in skeletal muscle and induced by Wy14,643, a PPARα activator, suggesting that the gene is regulated by PPARα (Motojima 2000). We found fenofibrate induced red muscle FABP at the transcriptional level.

It is presumed that FABPs serve as intracellular buffers of fatty acids, protecting cells from deleterious effects of excess free fatty acids by sequestering them inside the ligand cavity (Bernlohr et al. 1997). This could include a more specific role in scavenging of excess intracellular lipid content. The present study demonstrated that fenofibrate increased FABP in oxidative red muscle, probably facilitating the transport of fatty acids to mitochondria, and stimulated β-oxidative degradation of fatty acids. Scavenging of intracellular fatty acids in muscle might lead to a decrease in intramuscular triglyceride and result in improved insulin sensitivity.

The effects of fenofibrate on FABP in the soleus (red) and EDL (white) muscles were different in the present study. Red skeletal muscle (containing mainly slow-twitch oxidative fibers) differs from white skeletal muscle (containing fast-twitch glycolytic fibers) in several ways, including capillary density, oxidative enzyme content and mitochondria density. These inherent characteristics of red muscle account for its overall higher respiratory capacity and ability to oxidize fatty acids. Previous assessment of muscle FABP expression suggests that the levels of both protein and mRNA correspond to the oxidative fiber-type content in a given muscle (Peeters et al. 1991). It was also reported that red, but not white, muscle FABP was modulated in streptozotocin-induced diabetic rats known to increase fatty acid utilization (Carey et al. 1994). The modulation of muscle FABP may be predominant in red muscle compared with white muscle.

Previous reports showed that PPARα agonists such as bezafibrate (Si et al. 1999, Jonkers et al. 2001) and fenofibrate (Yong et al. 1999, Idzior-Walus et al. 2000) reduced blood pressure. It is speculated that this blood pressure-lowering effect is due to an enhancement of insulin sensitivity or an improvement in endothelial function. In the present study, fenofibrate treatment for 2 weeks improved insulin sensitivity but did not influence blood pressure. This discrepancy is probably due to the treatment period, which was shorter in the present study than in the previous studies (6–24 weeks). It was also reported that TSJN, a Chinese medicine used to treat diabetes mellitus, attenuated blood pressure in FFRs treated for 4 weeks but not those treated for 2 weeks despite improvement in insulin sensitivity (Li et al. 2000).

Taking this point into consideration, fenofibrate treatment for 2 weeks seems to be sufficient to ameliorate insulin resistance but not to reduce blood pressure.

In conclusion, the results from this study suggest that fenofibrate improves insulin sensitivity not only by lowering serum lipids and subsequent influx of fatty acids into muscles but also by reducing intramuscular lipid content via further induction of FABP and stimulation of β-oxidation in muscles.

References


DeFronzo RA & Ferrannini E 1991 Insulin resistance. A multifaced syndrome responsible for NIDDM, obesity, hypertension,


Received 25 February 2002
Accepted 8 April 2002